Wednesday, October 1, 2014 Last update: 11:03 AM - Tech News = Large & Small Companies (Many you've never heard of) Since 1996

KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson’s Disease, and Diabetic Neuropathy

Companies mentioned in this article: KineMed, Inc.

EMERYVILLE, Calif. -- (BUSINESS WIRE) -- KineMed, Inc. ( today announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: “Compositions and Methods of Treatment Using Modulators of Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the microtubule target modulating agent, noscapine, alone or in combination with a variety of other agents.

Based on KineMed’s research, the Company has shown that noscapine has the ability to normalize the disruption of microtubule turnover and neuronal transport of cargo proteins which characterize several neurodegenerative diseases, including ALS and Parkinson’s disease. KineMed has developed the first in vivo technique for accurately measuring these components of neuronal dysfunction in humans and experimental animals. “Patent protection of noscapine for use in ALS and Parkinson’s disease is critical for our plan to advance and de-risk this drug candidate. Our ability to identify precisely that a drug is hitting its pathophysiological target and to track its disease-modifying effect is unique in these serious neurodegenerative disorders. These proprietary diagnostic tools will also aid the development of other ALS drugs,” said David Fineman, KineMed Chairman and CEO.

About KineMed, Inc.

KineMed is a life sciences company that has developed a platform technology with broad applications in drug development and medical diagnosis. Using its patented technology, KineMed has developed analytic biomarker tests that measure, in a single sample, the rate of change of critical biological pathways. KineMed has the unique ability to measure the production and destruction of key molecules involved in health and disease-modifying biological processes to provide meaningful, and previously unavailable, information to transform healthcare decisions. For more information about KineMed, please visit:

Copyright © Business Wire 2014

KineMed, Inc.
Patrick Doyle, Ph.D., 510-655-6525 ext. 172
Cell: 415-906-9649
Chief Business Officer